title: Problems with the randomized discontinuation design.
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Hutson
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
authors.forename: William R
authors.initials: WR
authors.lastname: Berry
mesh_terms: D001557:Benzenesulfonates / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000379:methods*; D003627:Data Interpretation, Statistical; D004334:Drug Administration Schedule; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D000077157:Sorafenib; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib